Research analysts who have asked questions during Waldencast earnings calls.
LB
Linda Bolton-Weiser
D.A. Davidson & Co.
3 questions for WALD
Also covers: CLX, ELF, FLWS +14 more
Dana Telsey
Telsey Advisory Group
2 questions for WALD
Also covers: , AEO, AKA +44 more
JK
Jungwon Kim
BTIG, LLC
2 questions for WALD
Also covers: BBWI, BTMD, JILL +2 more
OT
Olivia Tong Cheang
Raymond James Financial, Inc.
2 questions for WALD
Also covers: BBWI, CHD, CL +13 more
Sydney Wagner
Jefferies
2 questions for WALD
Also covers: BBWI, COTY, ELF +5 more
AL
Alex Lake
Canaccord Genuity
1 question for WALD
AH
Ashley Helgans
Jefferies
1 question for WALD
Also covers: BBWI, COTY, ELF +9 more
John Chapman
Alliance Global Partners
1 question for WALD
JK
Jonna Kim
TD Cowen
1 question for WALD
Also covers: AEO, AKA, BBWI +5 more
LM
Lillian Moffett
Raymond James
1 question for WALD
Also covers: OLPX
Susan Anderson
Canaccord Genuity Group
1 question for WALD
Also covers: BODI, CDXC, COTY +13 more
Recent press releases and 8-K filings for WALD.
Waldencast strengthens balance sheet with trademark sale and credit facility refinancing
WALD
Debt Issuance
M&A
- Waldencast plc sold its rights to the "Obagi" trademark in Japan to Rohto Pharmaceutical Co., Ltd. for $82.5 million.
- The company secured a new three-year secured first-lien term loan facility of $225 million from funds managed by Lumina Capital Management Ltda. Group.
- The majority of the $82.5 million from the trademark sale will be used to promptly repay a significant portion of the new loan facility, deleveraging the balance sheet.
- These transactions are aimed at strengthening the balance sheet position and improving liquidity to support the growth of its Obagi Medical and Milk Makeup brands.
Nov 14, 2025, 10:00 PM
Quarterly earnings call transcripts for Waldencast.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more